Boehringer Ingelheim Animal Health Announces US Leadership Transition

Boehringer Ingelheim Animal Health, a leading provider of medicine for pets, horses and livestock, announced the appointment of Randolph Legg as its US President. He succeeds Everett Hoekstra, who retired in December.

Legg will remain head of the company’s US commercial business while serving as president.

“It’s my honor to lead an organization dedicated to enhancing the well-being of people and animals,” he said.

Legg held various commercial leadership roles in Boehringer Ingelheim’s Human Pharmaceutical division before moving to the company’s Animal Health business in 2019 to lead the US Pets Commercial team. He is based at the US headquarters of Boehringer Ingelheim Animal Health in Duluth, GA.

Hoekstra retired after holding a variety of leadership roles at Boehringer Ingelheim. As president of Boehringer Ingelheim Animal Health in the US for the last two years, he oversaw the final integration activities after Boehringer Ingelheim acquired Merial in 2017 to become the world’s second-largest animal health company.

Boehringer Ingelheim Animal Health also is transitioning a key global manufacturing role from its global headquarters in Ingelheim, Germany, to the United States. The company has named Dr. Helmut Finkler as Head of Regional Bio Manufacturing Americas & Global Manufacturing Science & Technology. He will oversee vaccine-production sites in the Americas, including in Athens, GA, Gainesville, GA, St. Joseph, MO and Guadalajara, Mexico. Finkler most recently served as Head of Global BIO Operations in Global Operations Animal Health.

Legg and Finkler report to Jean-Michel Boers, President and CEO of Boehringer Ingelheim USA Corp. He oversees Boehringer Ingelheim’s three business units in the United States: Human Pharmaceuticals, Animal Health and Bio-Pharmaceutical Contract Manufacturing.